Modified GRF 1-29 (AKA Mod GRF 1-29, CJC-1295 without DAC)
Half Life: 30 minutes
Overview and History of Modified GRF 1-29 (CJC-1295 without DAC)
Modified GRF 1-29 is also known as Mod GRF 1-29, but even more commonly known as CJC-1295 without DAC. The proper terminology, however, is its original name and classification: tetrasubstituted GRF (1-29). The confusion in regards to the naming and nomenclature of this particular substance must be first clarified before delving into any further discussion, as the majority of performance enhancing drug community and individuals looking to use this substance will undoubtedly become very confused upon reading and researching this product, and especially later on when electing to purchase it (it is listed under all of its names by some vendors and only one of its names by other vendors). The name Mod GRF 1-29 was originally derived by a researcher known as DatBtrue, who coined the term in his internet publicized articles on the substance. Because of the popularity of his articles, the new name was easily and extensively adopted by readers, and the common use of the name spread wildly from there. However, perhaps the most common name for this substance is CJC-1295 without DAC. The importance to understanding the difference in these names is the history of the substance and its structure.
Mod GRF 1-29 belongs to a category of peptides known as HGH (Human Growth Hormone) secretagogues. It is a modified derivative of an already existing derivative of Growth Hormone Releasing Hormone (GHRH), which is an endogenously produced peptide hormone in the human body. Therefore, it could be referred to more properly as a second generation derivative of GHRH. GHRH is modified to create what is known as Growth hormone Releasing Factor (GRF) 1-29. GRF 1-29 is then further modified to create Mod GRF 1-29. The nomenclature of the evolution of the derivatives should be self-explanatory concerning this. GRF 1-29 is also known by its trade name, Sermorelin (which Mod GRF 1-29 is a derivative of).
The most popular name for this peptide, however, is CJC-1295 without DAC, and is referred to as such because there is actually a third derivative of GHRH, which is known as CJC-1295 with DAC. The acronym DAC stands for Drug Affinity Complex, which is a modification that is added to the peptide that extends its half-life and active life in the body. CJC-1295 without DAC is simply Mod GRF 1-29.
For ease of explanation and clarification to the reader, what has been discussed thus far is the following:
GRF 1-29 is a modification of GHRH (Growth Hormone Releasing Hormone)
Mod GRF 1-29 is a modification of GRF 1-29
CJC-1295 with DAC is a modification of Mod GRF 1-29
Now that the confusing naming system has been clarified, the general description of Mod GRF 1-29 is as follows: Mod GRF 1-29 is a peptide hormone (also known as a protein hormone) that was developed in Canada and first mentioned in medical literature in 2005[i]. It is a protein that is 29 amino acids long, and as explained earlier, it is a GHRH analogue. As a GHRH analogue, Mod GRF 1-29 (CJC-1295 without DAC) acts on receptors at the pituitary gland to stimulate the release of Human Growth Hormone. In order to understand its function and what it is, one must understand the concept behind the protein/peptide structure of these hormones (which will also consequently help the reader to further understand the difference in the naming that has been discussed above).
Chemical Characteristics of Modified GRF 1-29 (CJC-1295 without DAC)
Proteins/peptides are chains of amino acids linked in specific unique orders. Proteins, depending on how many amino acids it is composed of, will manifest itself as one of three structural types: the primary protein structure which is simply a long chain of amino acids, the secondary protein structure which is a folded protein structure resembling a pleated sheet, the tertiary protein structure which is a complex fold of proteins that resembles a tangled ball of yarn, and finally the quaternary protein structure which is several tertiary proteins interconnected. The significance of this in protein hormones such as Human Growth Hormone (HGH), insulin, Luteinizing Hormone (LH), Mod GRF 1-29 (CJC-1295 without DAC), and many others, is the fact that various sections of the protein structure will contribute to different jobs in the body by binding to and activating different receptors. The shape of the peptide hormone, and the different subsections of it, can allow stronger binding affinity or weaker binding affinity.
Growth Hormone Releasing Hormone (GHRH), which is the endogenously secreted GHRH by the arcuate nucleus of the hypothalamus of the human body, is 44 amino acids long. It was discovered, however, that only the first 29 amino acids of the protein were equally as effective in binding to receptors on the pituitary gland as the full 44 amino acid structure[ii] [iii]. The first 29 amino acids in its protein structure were then isolated, which was then called GRF 1-29, but the problem with this derivative of GHRH was the fact that it was rapidly metabolized and cleared from the body by enzymes. Studies have reported that GRF 1-29’s half-life is less than 10 minutes and as little as 5 minutes[iv]. This was obviously not enough time to ensure a maximized and sustained release of HGH from the pituitary gland, as studies have demonstrated that the full potential of an HGH pulse from the pituitary requires at least 30 minutes as evidenced by the fact that much higher HGH levels (50 times greater) were observed 15 – 30 minutes into subcutaneous administration of GHRH analogues[v].
Therefore, the solution to this was to modify GRF 1-29 by replacing various amino acids in its structure with other amino acids that would provide a greater resistance to breakdown and cleavage by enzymes. There were many modified analogues developed, and Mod GRF 1-29 (CJC-1295 without DAC) was eventually selected for use, which demonstrated the most promising effects. Mod GRF 1-29 is a modification of GRF 1-29, specifically at amino acids #2, #8, #15, and #27. The result is an extended half-life to that of at least 30 minutes[vi] [vii].
Properties of Modified GRF 1-29 (CJC-1295 without DAC)
Mod GRF 1-29 acts upon receptors located in the anterior pituitary gland, and signals the pituitary gland to increase Human Growth Hormone production and cause a release of massive quantities of Human Growth Hormone in a pulsatile manner. The effects of Mod GRF 1-29 are very similar from what would be expected from synthetic HGH administration over the long term (see the Human Growth Hormone profile here), although the amount of time that the released human growth hormone will remain in circulation is of a far less amount of time than synthetic Human Growth Hormone does. Therefore, multiple applications of Mod GRF 1-29 is recommended throughout the day in order to simulate Human Growth Hormone levels that remain high on a constant basis. Mod GRF 1-29 (CJC-1295 without DAC) is commonly combined with a Ghrelin mimetic (also known as a GHRP – Growth Hormone Releasing Hexapeptide), such as GHRP-6, GHRP-2, Hexarelin, or Ipamorelin in order to initiate and amplify a greater pulse of HGH from the pituitary compared to Mod GRF 1-29 used solitarily on its own. The effects of a GHRH analogue (such as Mod GRF 1-29) and a Ghrelin mimetic (a GHRP such as GHRP-6 or Ipamorelin) are synergistic and amplify the release of HGH from the pi
CJC-1295 Side Effects
The side effects associated with Mod GRF 1-29 can all be attributed to Human Growth Hormone’s side effects, seeing as though the actual specific end result of Mod GRF 1-29 (CJC-1295 without DAC) is to achieve vast increases of naturally occurring endogenously produced Human Growth Hormone. Therefore, it is important to understand that Mod GRF 1-29 side effects are primarily and almost exclusively resultant of the HGH increase it will trigger in the human body. Neither HGH, nor Mod GRF 1-29, are sex hormones and therefore no side effects of the types associated with anabolic steroids can be expected (such as androgenic side effects and virilization, etc.). Therefore, Mod GRF 1-29 is just as well suited for female use as it is for male use. Mod GRF 1-29 side effects alone are considered to be minimal to the point of almost nonexistent, although some adverse reactions have been reported such as nausea, vertigo, and light-headedness. In fact, especially when combined with a GHRP, Mod GRF 1-29 will almost always cause what is commonly known as a “head rush” feeling accompanied by a tingling and “pins and needles” feeling in the extremities, as reported by many users. This is in fact a strong indication that the hormone is indeed stimulating the pituitary gland.
Aside from Mod GRF 1-29 side effects that are excusive to the peptide itself, there are of course all of the side effects associated with Human Growth Hormone as previously touched upon. These include the most common side effects such as: flu-like symptoms, joint pain, and carpal tunnel syndrome, headaches, and bloating and water retention. Less likely side effects include: dizziness, tingling or numbness on the skin, reduction of touch sensitivity, nausea, sore bones, and gynecomastia. Although HGH is not a sex hormone, it does serve as an important mediator hormone that works with Estrogen in the development of gynecomastia. This should be kept in mind when utilizing Mod GRF 1-29 (or any HGH related compound) with aromatizable anabolic steroids.
For a more in-depth descriptive list of side effects resultant from Human Growth Hormone use, please see the Human Growth Hormone Side Effects section of the Human Growth Hormone profile.
CJC-1295 Cycles and Uses
Mod GRF 1-29 is a peptide hormone that, as previously explained, signals the release of endogenously manufactured Human Growth Hormone from the pituitary gland as opposed to administering exogenous synthetic HGH through injection. Therefore, for all intents and purposes, Mod GRF 1-29 is considered a type of Human Growth Hormone product/compound. It must be made clear that it is not Human Growth Hormone itself, but that it causes a pulsatile release of endogenously manufactured Human Growth Hormone.
Therefore, Mod GRF 1-29 cycles should essentially be treated more or less the same way that exogenous HGH cycles are treated. These types of cycles are very different from anabolic steroid cycles, and therefore they cannot be regarded or treated as such. There is no such thing as “beginner Mod GRF 1-29 cycles” or “advanced Mod GRF 1-29 cycles” due to the inherent nature of the compound. Mod GRF 1-29 (CJC-1295 without DAC) holds very broad application in its use, and its dosing frequency is the only determining factor in what results will manifest according to the individual user’s goals. Mod GRF 1-29 cycles can be essentially broken down into three main categories:
– Mod GRF 1-29 cycles for muscle growth and fat loss
– Mod GRF 1-29 cycles for fat loss
– Mod GRF 1-29 cycles for anti-aging and general well-being
The nature of all Human Growth Hormone cycles (and therefore every Mod GRF 1-29 cycle) is that of a long-term cycle. Human Growth Hormone and Mod GRF 1-29 cycles are long-term in the range of at least 4 – 6 months in length. This is very different from anabolic steroid cycles that are ranged in the time window of weeks rather than months. This is because the nature of Human Growth Hormone and its effects on the body are cumulative and steady, with results not typically observed until several weeks into use, and results typically become more pronounced as time moves further on into the cycle.
Mod GRF 1-29 cycles for muscle growth and fat loss together involve the administration of 100mcg of Mod GRF 1-29 (CJC-1295 without DAC) at least three times per day for 4 – 6 months. Ideally, for both pronounced muscle growth as well as fat loss, a user should perform 4 – 5 administrations of Mod GRF 1-29 per day, ensuring each administration is no less than 3 hours apart, for 4 – 6 months. The increased amount of HGH pulses from the pituitary gland should ensure constant steady elevations of naturally occurring endogenous HGH.
Mod GRF 1-29 cycles for fat loss alone requires the administration of 100mcg of Mod GRF 1-29 (CJC-1295 without DAC) two to three times per day (but ideally three times per day) for 4 – 6 months. Such an application should provide enough HGH pulses to ensure that the lipolytic benefits are experienced. Some muscle accrual, depending on nutrition and training, can also be experienced.
Mod GRF 1-29 cycles for anti-aging and general well being requires the administration of 100mcg of Mod GRF 1-29 (CJC-1295 without DAC) one to two times per day for 4 – 6 months. Although HGH pulses from the pituitary gland are at a minimum with such a Mod GRF 1-29 cycle, such a protocol should ensure that there is enough HGH released to provide general healing, recuperation, anti-aging, and increased well being.
It is very important to note that the cycle length and the doses provided will not determine whether a particular Mod GRF 1-29 cycle will produce fat loss and/or muscle growth – nutrition and training will dictate this! The compound itself will simply assist the user in traveling faster in the direction of his or her goals, but the steering into such a direction is determined by properly adjusted nutrition and training to meet those goals. For enhanced benefits from Mod GRF 1-29 (CJC-1295 without DAC) cycles, it is ideal that it is stacked with a GHRP of some sort, as previously mentioned in this profile, in order to allow proper synergy for greater HGH pulses.
Mod GRF 1-29 cycles can also easily be run alongside synthetic HGH, anabolic steroids, and other peptides such as IGF-1. Although Mod GRF 1-29 cycles should be run in the long-term in the range of at least 4 – 6 months or greater, the occasional anabolic steroid cycle can indeed be inserted periodically throughout this period in order to take full advantage of the synergistic effects of anabolic steroids with the Human Growth Hormone increases that are triggered by the Mod GRF 1-29 (CJC-1295 without DAC). The combination of synthetic exogenous HGH with Mod GRF 1-29 is very common among those who can afford it, who will typically administer their exogenous synthetic HGH at a dose of 4iu immediately in the morning, followed by administrations of Mod GRF 1-29 mid-day (with another optional HGH administration 30 minutes after that), and then finally another Mod GRF 1-29 administration immediately before going to bed. Such a protocol in a Mod GRF 1-29 cycle ensures maximum benefit of HGH and is much more cost effective for the user than resorting to larger doses of synthetic HGH alone.
CJC-1295 Administration and Dosages
Mod GRF 1-29, as well as the majority of other growth hormone releasing peptides, are very new substances on the market, and there exists at this point in time (as of 2013) a limited amount of clinical data and general information in regards to Mod GRF 1-29 doses. Solid protocols have indeed been developed, but what should be noted is that Mod GRF 1-29 (CJC-1295 without DAC) is yet to be approved or utilized in medicine, and clinical trials of Mod GRF 1-29, as well as many other peptide hormones, are still in the midst of research. With that having been said, the limitation of clinical data and general information on CJC-1295 without DAC doses have not prevented athletes, bodybuilders, and those within the performance enhancing drug using community from taking advantage of its effects through use. Therefore, there is enough data currently to provide information on proper and effective Mod GRF 1-29 doses.
Natural endogenously produced GHRH is secreted by the hypothalamus, and travels directly to the anterior pituitary gland in order to bind to receptors there and stimulate HGH release. GHRH and its analogues (like Mod GRF 1-29) have a tendency to already possess very short half-lives due to the high affinity for the bonds between the amino acids in the peptides to be cleaved by enzymes in the body. Because naturally secreted GHRH does not travel very far between the hypothalamus and the pituitary gland, very little of it is broken down by enzymes during travel. However, Mod GRF 1-29 and related GHRH analogues must travel a long ways to the pituitary gland through circulation after injection, and within approximately 3 minutes, breakdown of the peptide already occurs. Therefore, Mod GRF 1-29 doses must be high in comparison to endogenously produced GHRH in order to achieve saturation of the receptors on the anterior pituitary.
Saturation doses are defined as doses that fully saturate the target receptors in the body (in this case, the receptors located on the anterior pituitary). This means that a 100mcg saturation dose will fully saturate receptors, and that 200mcg will only provide 50% additional effectiveness, and a 300mcg dose will provide only 25% additional effectiveness, and so on and so forth.
Mod GRF 1-29 doses are measured in mcg (micrograms), and readers should take note of this due to the common measurement of other performance enhancing drugs (such as anabolic steroids) in mg (milligrams). Synthetic Human Growth Hormone (HGH) is measured in iu (international units). The difference in distinguishing between the different dosing measurements must be taken into account.
Medical Modified GRF 1-29 (CJC-1295 without DAC) Doses
Because Mod GRF 1-29 (CJC-1295 without DAC) is not currently yet approved for medical use and is still in the phase of clinical trials, there are no prescription medical doses currently available.
Mod Modified GRF 1-29 (CJC-1295 without DAC) Doses for Performance and Physique Enhancement
For the purpose of performance and physique enhancement, peptides such as Mod GRF 1-29 in particular cannot be categorized into the three tiers of users (beginner, intermediate, and advanced) due to the inherent nature of the type of substance and hormone. As a result, there is a general single across-the-board protocol of Mod GRF 1-29 doses that have been determined and established, as the increases of HGH from the pituitary are generally large enough to benefit any person.
Research has demonstrated that an effective saturation dose of Mod GRF 1-29 is 100mcg/kg of bodyweight   . 100mcg of Mod GRF 1-29 would require an individual who is 100kg of bodyweight, which is 220 lbs. Therefore, for ease of administration and confusion, the standard general Mod GRF 1-29 dose is that of 100mcg for nearly all users in order to achieve saturation of the receptors on the anterior pituitary gland at any given time. 100mcg should be administered three times per day spaced evenly apart in order to achieve substantial HGH levels throughout the day due to its short 30 minute half-life, and the pulsatile manner of the HGH release that it causes (this will be further explained shortly).
Female Modified GRF 1-29 (CJC-1295 without DAC) Doses
Mod GRF 1-29 is not a sex-specific hormone and therefore carries no androgenic effects that would present any issues. Therefore, female Mod GRF 1-29 doses are the exact same as that of males and everyone else.
Proper Administration and Timing of Modified GRF 1-29 (CJC-1295 without DAC) Doses
Mod GRF 1-29 is typically manufactured as lyophilized (freeze-dried) powder in amounts of 2mg per vial. This powder within the vial must be reconstituted with bacteriostatic water before injection, and promptly refrigerated after constitution and after each use due to its peptide nature. If left unrefrigerated at room temperature for extended periods of time, the reconstituted peptide will quickly degrade and become ineffective. When reconstituting, typically 2ml of bacteriostatic water is gently mixed into the powder (normally an amount of 2mg of powder) which will then yield a Mod GRF 1-29 dose of 100mcg per 0.1ml (or 10iu on an insulin syringe).
Mod GRF 1-29 (CJC-1295 without DAC) can be administered subcutaneously (SQ) or intramuscularly (IM). There is not much difference between the two, with intramuscular seemingly resulting in a slightly quicker release from the injection site. The majority of individuals prefer to administer it subcutaneously for varying reasons, however.
There are a few important points to consider and understand concerning Mod GRF 1-29 doses (or doses of any type of GHRH). The first point is that administration of any GHRH should be done no sooner than 30 minutes prior to any meal containing fats and carbohydrates, and at least 2 hours following any meal containing fats and carbohydrates. This is because fats and carbohydrates both exhibit a blunting effect on the release of HGH from the pituitary gland, and therefore consuming these two macronutrients too soon before or after administration will hamper the full pulse of HGH release from the pituitary. Once HGH levels have reached their peak from the pulse, which is 30 minutes following administration, it will then be safe to consume a meal containing carbohydrates and fats.
Because GHRH analogues such as Mod GRF 1-29 (CJC-1295 without DAC) stimulate HGH release in a pulsatile manner, multiple Mod GRF 1-29 doses are required throughout the day that are typically administered on average 3 times daily spaced evenly apart. The most common protocol is as follows:
100mcg immediately upon waking up
100mcg immediately following the end of a workout
100mcg immediately before bed
The three times per day application of 100mcg of GRF 1-29 doses is said to provide HGH release that is desired for bodybuilding and performance enhancement. Some opt for twice daily application (100mcg in the morning and before bed), which is said to provide HGH release that is desired for anti-aging and general health benefits. Some will opt to also administer Mod GRF 1-29 (CJC-1295 without DAC) even more than three times per day, which would obviously generate much higher levels of HGH. However, it is important to ensure at least 3 hours between each administration of any GHRH so as to ensure adequate HGH levels are once again restored within the pituitary for optimal release.
It has been previously mentioned that GHRH analogues such as Mod GRF 1-29 should typically be utilized with a GHRP (also known as a Ghrelin mimetic) such as GHRP-6 or Ipamorelin. This is because GHRH and GHRP peptides are synergistic in the manner by which they stimulate the anterior pituitary to release HGH. GHRH alone is only effective when Somatostatin (a hormone that inhibits HGH release from the pituitary) is low. Any GHRP will serve to inhibit Somatostatin and this will serve as one of the multiple methods that GHRPs will potentiate Mod GRF 1-29’s (or any GHRH’s) effects. In general summary of the synergistic effect of both: a GHRH analogue (such as Mod GRF 1-29) will serve to initiate and carry forward the pulse of HGH from the pituitary gland, while the GHRP (such as GHRP-6) will serve to amplify this pulse.
Lastly, a single administration of 100mcg of any GHRH by itself resulted in 25ng/ml of HGH released from the pituitary according to studies. The same study determined that when combined with a GHRP (GHRP-6), the resultant HGH release was determined to be 130 ng/ml.
Expectations and Results from Modified GRF 1-29 (CJC-1295 without DAC) Doses
Results and expectations from an HGH secretagogue such as Mod GRF 1-29 should be all of the same effects that any other form of Human Growth Hormone would provide. This includes fat loss, muscle mass increases, strength gains, healing and repair of joints and connective tissue, and a plethora of other benefits and changes. An important note to make is that the effects from any HGH application, whether it be an endogenous release from a GHRH or synthetic HGH administration, will all occur rather steadily over a longer period of use. Dramatic results within weeks are never to be expected, but with proper nutrition and training, dramatic performance and physique changes should occur steadily over the course of several months of application. For more information on HGH specific results and expectations, please see the Human Growth Hormone profile.
Buy CJC-1295 Online and Legality:
Mod GRF 1-29 is a very new peptide on the market, so those who wish to buy Mod GRF 1-29 will be happy to know that it is generally legally available in almost every country as a research chemical. It’s manufacture is fairly simple compared to other peptides, and because there is no legislation placed upon it, it is freely sold on the open market without fear of legal repercussion.
Those looking to buy Mod GRF 1-29 will find almost exclusively research grade product. With this being said, research grade Mod GRF 1-29 is typically sold as lyophilized (freeze-dried) powder in amounts of 2mg per vial. This vial must be reconstituted with bacteriostatic water before injection. Research grade Mod GRF 1-29 can be purchased for $22 – $45 per 2mg vial, depending on which research chemical company is selling it.
Mod GRF 1-29 is currently legally available as a research chemical in the United States, Canada, and the UK as well as the majority of nations on earth. It is as of yet still in clinical research phases within the medical establishment, and there are no scheduling’s or controls placed upon the peptide as of yet in most major countries. There are also no laws against personal use of Mod GRF 1-29, but every reader should understand that the only available Mod GRF 1-29 is for research purposes only and not for human use.
[i] Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Endocrinology. 2005 Jul;146(7):3052-8. Epub 2005 Apr 7.
[ii] In vivo biological potency of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor. Wehrenberg WB, Ling N. (1983). Biochem Biophys Res Commun 115 (2): 525–530. doi:10.1016/S0006-291X(83)80176-4
[iii] Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults. Grossman A, Savage MO, Lytras N, et al. (1984). Clin Endocrinol (Oxf) 21 (3): 321–330.
[iv] Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. Frohman LA (1986). J Clin Invest 78 (4): 906–913. doi:10.1172/JCI112679.
[v] Potent trypsin-resistant hGH-RH analogues. Izdebski J, Witkowska E, Kunce D, Orłowska A, Baranowska B, Wolińska-Witort E. J Pept Sci. 2004 Aug;10(8):524-9.
[vi] New potent hGH-RH analogues with increased resistance to enzymatic degradation. Izdebski J (2002). JJ Pept Sci. 8 (7): 285–287.
[vii] Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). Endocrinology 146 (7): 3052–8.
] EFFECTS OF A GRCWTH HORMONE RELEASING FACTOR IN MAN. Marie C. Gelato, Ora Pescovitz, Fernando Cassorla, D. lynn Fernando and George R. Merriam. The Journal of Clinical Endocrinology & Metabolism September 1, 1983 vol. 57 no. 3 674-676.
 α2-Adrenergic Agonism Enhances the Growth Hormone (GH) Response to GH-Releasing Hormone through an Inhibition of Hypothalamic Somatostatin Release in Normal Men*. JESUS DEVESA, VICTOR ARCE†, NOEMI LOIS, JESUS A. F. TRESGUERRES and LUIS LIMA. The Journal of Clinical Endocrinology & Metabolism December 1, 1990 vol. 71 no. 6 1581-1588
 Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons. L Lima, V Arce, M J Diaz, J A Tresguerres and J Devesa. The Journal of Clinical Endocrinology & Metabolism February 1, 1993 vol. 76 no. 2 439-444.
 Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Lucie Jetté, Roger Léger, Karen Thibaudeau, Corinne Benquet, Martin Robitaille, Isabelle Pellerin, Véronique Paradis, Pieter van Wyk, Khan Pham and Dominique P. Bridon. Endocrinology July 1, 2005 vol. 146 no. 7 3052-3058.
 Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing’s syndrome. Leal-Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva FF. Clin Endocrinol (Oxf). 1994 Nov;41(5):649-54.